Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research
Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research
VANCOUVER, BC / ACCESSWIRE / September 14, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), Chief Executive Officer Justin Hanka provides corporate update on depression trials and other important developments in the Company in this video address to shareholders.
溫哥華，BC/ACCESSWIRE/2023年9月14日/MindBio Treateutics Corp.(CSE：mBio)(法蘭克福：WF6)，(“公司“或”MindBio“)，首席執行官賈斯汀·漢卡在這段向股東發表的視頻講話仲介紹了公司關於抑鬱症試驗和其他重要發展的最新情況。
In this video, Justin Hanka, Chief Executive Officer of MindBio, discusses:
在這段視頻中，MindBio首席執行官賈斯汀·漢卡討論了：
-Progress in MindBio's Phase 2a Microdosing Clinical Trial using MB22001, a proprietary form of LSD for Microdosing.
-MindBio公司使用MB22001進行的2a期微劑量臨床試驗的進展，MB22001是一種用於微劑量的專有形式的LSD。
-A breakthrough genetic discovery important to predicting patient vulnerability in certain genotypes
-一項突破性的基因發現，對預測某些基因類型的患者易感性很重要
-The unexpected discovery of sleep improvement from MB22001 use, including increases in total time of sleep and REM sleep from 3200 days of sleep data
-使用MB22001意外發現睡眠改善，包括從3200天的睡眠數據增加總睡眠時間和快速眼動睡眠
The company is expecting a top line read out from its Phase 2a Depression trial by the end of the year.
該公司預計，今年年底將公佈2a期抑鬱症試驗的營收數據。
We invite you to join us in support of creating a brighter future for mental health.
我們邀請您加入我們，支持為心理健康創造更美好的未來。
Receive our latest updates here:
點擊此處接收我們的最新更新：
Follow MindBio on LinkedIn:
在LinkedIn上關注MindBio：
Follow CEO Justin Hanka on LinkedIn:
在領英上關注首席執行官賈斯汀·漢卡：
For further information, please contact:
如需更多資訊，請聯繫：
Justin Hanka, Chief Executive Officer
61 433140886
justin@mindbiotherapeutics.com
首席執行官賈斯汀·漢卡
61 433140886
郵箱：justin@Mind BioTreateutics.com
About MindBio Therapeutics
關於MindBio治療學
MindBio is a biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home LSD-Microdosing human clinical trials. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials microdosing Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2 clinical trial in development microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial in development microdosing LSD in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.
MindBio是一家生物技術/生物製藥公司，專注於為精神健康疾病創造新的和新興的治療方法，並正在進行世界上第一個帶回家的LSD微劑量人體臨床試驗。MindBio是迷幻藥物微劑量領域的領先者，正在通過臨床試驗推進其藥物和技術方案。MindBio已經開發了一個開發治療方法的多學科平臺，並參與了迷幻藥物的開發和數字治療，已經完成了在80名患者中使用微劑量麥角酸二乙醯胺(LSD)的第一階段臨床試驗，在開發針對嚴重抑鬱障礙患者的微劑量LSD的第二階段臨床試驗，以及在開發微劑量LSD用於經歷生存困境的晚期癌症患者的第二階段臨床試驗。MindBio投資於研究，這些研究構成了開發新型和臨床驗證的治療方法的基礎，包括數位技術和幹預措施，以治療抑鬱症、焦慮症和其他相關精神健康疾病等令人衰弱的健康狀況。
Cautionary Note Concerning Forward-Looking Statements:
有關前瞻性陳述的注意事項：
The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.
該新聞稿包含適用證券法所指的“前瞻性陳述”。前瞻性陳述可以用下列詞語來識別：“預期”、“打算”、“計劃”、“預算”、“相信”、“專案”、“估計”、“預期”、“預定”、“預測”、“戰略”、“未來”、“可能”、“可能”、“將是”、“可能”、“將”、“應該”，“將”和類似的對未來期間或否定或可比術語的引用，以及通常用於未來和有條件的術語。前瞻性陳述是基於截至提供這些陳述之日的假設。然而，不能保證這些假設將反映這些專案或因素的實際結果。
Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.
此外，還有一些已知和未知的風險因素可能會導致公司的實際結果和財務狀況與前瞻性陳述中指出的大不相同。因此，您不應依賴這些前瞻性陳述中的任何一種。可能導致實際結果和財務狀況與前瞻性陳述中指出的大不相同的重要風險因素包括：加拿大和澳大利亞的總體經濟、市場和商業狀況；市場波動；本新聞稿中描述的任何交易或事件的時間安排的意外延遲。所有前瞻性資訊均受本警告性聲明的限制。
The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
公司沒有義務修改或更新任何此類前瞻性陳述，也沒有義務公開宣佈對本文中包含的任何前瞻性資訊的任何修改結果，以反映未來的結果、事件或發展，除非法律另有要求。
Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
SOURCE: MindBio Therapeutics
資料來源：MindBio治療